According to the Zhixin Finance and Economics App, Concord JieRui Pharmaceuticals-B (09966) soared 19% and rose 19.08% to HKD 3.02 at the time of publication, with a turnover of HKD 87.0057 million.
On the news front, Concorde JieRui Pharmaceuticals recently announced that the Phase I clinical trial data of its new anti-HER2 dual-site targeting antibody-conjugated drug (ADC) JSKN003 for the treatment of HER2-expressing solid tumors in China will be first announced at the 2024 ASCO Annual Meeting. The study concluded that JSKN003 has good tolerability and controllable safety in advanced/metastatic solid tumor patients previously treated with multiple systemic therapies. Currently, multiple clinical studies of JSKN003 are underway in Australia and China, and the key clinical research for the treatment of advanced HER2-low-expressing breast cancer in China is also actively progressing.